Overall Score

Scale Market Position

AVDL remains a small-cap biotech with a market cap of about $2.12B, limiting scale advantages versus larger peers.

Revenue per share of $2.04 and asset turnover near 1.0x suggest a commercial footprint, but not a dominant one.

Profitability Cash Generation

Gross margin is very high at 95.5%, but operating margin is only 4.0% and net margin is 2.4%, indicating limited pricing power at the operating level.

Free cash flow is positive, but FCF yield is only 1.3% and valuation multiples remain elevated, which tempers moat confidence.

Balance Sheet Resilience

Liquidity is solid with a current ratio of 2.76x and quick ratio of 2.37x, supporting near-term resilience.

Net debt is negative relative to EBITDA and debt-to-capital is 27.6%, suggesting manageable leverage.

Capital Efficiency Returns

Return on invested capital of 5.7% and return on equity of 5.4% are modest, implying only limited economic moat evidence.

Interest coverage of 1.12x remains thin, so returns are not yet strong enough to indicate durable excess economics.

Competitive Intangibles

High gross margins and a strong cash position may reflect some product differentiation, but the data does not yet show a clear, durable moat.

R&D intensity at 18.0% of revenue indicates ongoing innovation investment, but not necessarily entrenched competitive advantage.